The Breast Cancer Therapeutics Market in Australia
SYDNEY, Aug. 5 /PRNewswire/ -- Rising public awareness of breast
cancer and available treatments have increased revenues in the breast
cancer therapeutics market in Australia. As the most common cancer diagnosed in Australia's female population, the total number of breast
Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial
TAMPA, Fla., July 14 /PRNewswire/ -- Quantum Immunologics, Inc. (QI), a Tampa, Florida company focusing on the research and development of cancer immunotherapies, announces that the first patient in its breast
cancer trial has begun to receive its dendritic cell therapy.
Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer
RARITAN, N.J., July 13 /PRNewswire/ -- Measuring the change in circulating tumor cell (CTC) count can accurately predict the prognosis and survival in patients with metastatic breast
cancer (MBC), according to a newly published report in the July 10 issue of the Journal of Clinical Oncol...
New MRI technique could mean fewer breast biopsies in high-risk women
MADISON A University of Wisconsin-Madison biomedical engineer and colleagues have developed a method that, applied in MRI scans of the breast, could spare some women with increased breast
cancer risk the pain and stress of having to endure a biopsy of a questionable lump or lesion.
Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
- Guidelines Specify that Validated Molecular Assays Should be Considered as an Adjunct to Standard Measures in Helping Determine Chemotherapy Benefit -
GENEVA, and REDWOOD CITY, Calif., June 26 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX ) today reported that the St. Galle...
Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer
SEATTLE, June 22 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) (TSX:ONY) (the "Company") today announced that Merck KGaA of Darmstadt, Germany, has initiated a global Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine, L-BLP25) in patients with hormone receptor-positive, locally ad...
DNA Genotek Partners with Roswell Park Cancer Institute to Accelerate Breast Cancer Research
DNA Genotek to Provide Method for Easy, Reliable and Non-Invasive DNA Collection On-Site at Komen Western New York Race for the Cure®
Ottawa, ON (PRWEB) June 12, 2009 -- DNA Genotek , a leading provider of products for biological sample collection, today announced ...
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
- Interim Primary Endpoint Data from Phase II Study Shows 71% Objective Tumor Response Rate in Evaluable Patients Receiving Bavituximab Plus Docetaxel -
- Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free Survival in Initial Study Cohort -
ORLANDO, Fla. and ...
Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
HUNTINGTON BEACH, California and AMSTERDAM, May 21 /PRNewswire/ --
Agendia, a world leader in molecular cancer diagnostics, today announced that
leading researchers from Agendia, the University of California San Francisco
and the Netherlands Cancer Institute will present data from multiple s...
Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
BONITA SPRINGS, Fla., April 30 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, announced that preclinical data were presented on its novel molecule, AFP-464, during the recent AACR 100th Annual Meeting 2009 in Denver. "This research represents a significan...
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
- Updated Data from Initial Cohort Shows Nine of 14 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response -
- Patient Dosing Underway in Expansion Stage of Trial with Target of Enrolling 46 Patients Overall -
Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
FOXA1 biomarker predicts likelihood of recurrence and long-term disease-free survival of breast
cancer patients; Further strengthens Company's breast
ALISO VIEJO, Calif., April 23 /PRNewswire-FirstCall/ -- Clarient, Inc. , (Nasdaq: CLRT ), a premier anatomic pathology and mol...
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(T...
Agendia Presents Data Supporting MammaPrint's Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands, March 11
/PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics,
today announced that leading researchers from Agendia and the Netherlands
Cancer Institute will present data from multiple studies at the 2009
Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
MOUNTAIN VIEW, Calif., Feb. 19 /PRNewswire/ -- Based on its recent analysis of the medical imaging market, Frost & Sullivan presents Naviscan, Inc. with the 2009 North American Frost & Sullivan Award for Emerging Technology of the Year. The Award recognizes the company's impressive progre...
New Study Reports Improved Patient Outcomes for Breast Cancer Patients
VALENCIA, Calif., Feb. 18 /PRNewswire/ -- A new clinical study published this month in The Breast
Journal (Vol. 15, No. 1) reports that high-quality patient outcomes for breast-conserving surgery can be achieved in the community hospital setting. This is one of the few and the most recent studie...
Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
HUNTINGTON BEACH, California, and AMSTERDAM, February 18 /PRNewswire/ --
Agendia, a world leader in molecular cancer diagnostics, today announced that
a study demonstrating the direct predictive ability of its breast
recurrence test, MammaPrint(R), has been published in Breast
Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
PRINCETON, N.J., Feb. 5 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, today announced the publication of data from a phase I/II study of nonpegylated liposomal doxorubicin (Myocet(R)) in the Janua...
Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
HUNTINGTON BEACH, California and AMSTERDAM, February 4 /PRNewswire/ --
Agendia, a world leader in molecular cancer diagnostics, today announced that
its signature breast
cancer test MammaPrint(R) will be offered as standard of
care for all eligible early stage breast
cancer patients at the Net...
BioStorage Technologies Partners with Susan G. Komen for the Cure(R) Tissue Bank at the IU Simon Cancer Center in Breast Cancer Research Initiative
INDIANAPOLIS, Jan. 6 /PRNewswire/ -- The Susan G. Komen for the Cure(R)
Tissue Bank at the IU Simon Cancer Center in Indianapolis has partnered with
BioStorage Technologies, Inc. (BST) for secure, compliant storage of donated
tissue specimens. BST will store a third of the tissue bank's existi...
Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
EMERYVILLE, Calif., Dec. 12 /PRNewswire-FirstCall/ -- Bionovo, Inc.
(Nasdaq: BNVI ) will present findings on the mechanism of action of its
anti-cancer agent BN107 at the 31st Annual San Antonio Breast
being held at the Henry B. Gonzalez Convention Center, San Antonio TX,
Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA
CHICAGO, Dec. 5 /PRNewswire/ -- Early clinical experience with the FDA
cleared Visica 2(TM) Treatment System from Sanarus Medical confirms the
effectiveness of ultrasound guided cryoablation to completely eradicate
small, unifocal Invasive Ductal Breast
Cancer (IDC). Initial data from this
Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
REDWOOD CITY, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Genomic Health,
Inc. (Nasdaq: GHDX ) today announced that the company will present results from
four studies at the 31st Annual San Antonio Breast
Cancer Symposium, taking
place December 10-14, 2008, at the Henry B. Gonzalez Convention Cente...
New Program Offers Breast Cancer Clinicians and Patients Support for Pre-Operative Clinical Assessment and Ongoing Surveillance of Lymphedema
NEWPORT NEWS, Va., and SAN DIEGO, Dec. 2 /PRNewswire/ -- The Patient
Advocate Foundation (PAF), with support from ImpediMed Ltd. (ASX: IPD), is
pleased to announce the launch of the Lymphedema CareLine (LCL). PAF, through
its MedCare Division, is offering the national, toll-free patient/provider
China Medical Technologies Receives SFDA Approval for Breast Cancer HER-2 FISH Probe
- the First SFDA Approved FISH Probe in China
BEIJING, Nov. 12 /Xinhua-PRNewswire-FirstCall/ -- China Medical
Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based
medical device company that develops, manufactures and markets advanced in-
vitro diagnostic pro...
Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
- Seventh Study Showing Oncotype DX Frequently Changes Treatment Recommendations in Clinical Practice -
REDWOOD CITY, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Genomic Health,
Inc. (Nasdaq: GHDX ) today announced the publication of results from a study
indicating that Onco...
Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
SAN MARINO, Calif., Oct. 29 /PRNewswire/ -- Epeius Biotechnologies
Corporation announced today the expansion of clinical trials using
intravenous Rexin-G for pancreatic cancer and breast
cancer in Manhattan,
New York. Rexin-G is the world's first tumor-targeted genetic medicine that
Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
OSLO, October 28 /PRNewswire-FirstCall/ -- DiaGenic ASA (OSL:DIAG)
today announced that it has signed a service provider agreement with
DNAVision, a leading panEuropean provider of gene expression-based
diagnostic testing and services With this laboratory service and following
CE marking sched...
James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30
Xceed Molecular will feature Ziplex automated gene-expression system at the conference, booth 519
WELLESLEY, Mass., Oct. 28 /PRNewswire/ -- Xceed Molecular, a pioneer in
the development of cost-effective, easy-to-use gene-expression analysis
systems, announced that renown...
Brain Fitness Program Offers Hope for Breast Cancer Survivors Suffering From 'Chemobrain'
SAN FRANCISCO, Oct. 24 /PRNewswire/ -- Researchers at 28th annual
National Academy of Neuropsychology (NAN) Conference in New York City this
weekend will present data to help physicians understand more about
cognitive remediation training in breast
cancer survivors affected by
Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
BOSTON, Oct. 23 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink
Sheets: SNDY) is pleased to announce that advanced breast
through the use of mammary ductoscopy was a featured topic and reviewed in
panel discussions at the 94th Annual American College of Surgeons Clinical...
Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
-Data Update Shows 71% of Evaluable Patients in the Trial's First Stage Achieved Objective Tumor Responses- -Patient Enrollment is Open in the Trial's Second Stage-
TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Peregrine
Pharmaceuticals, Inc. (Nasdaq: PPHM ), a cli...
Amoena Helps Women Re-shape Their Lives After Breast Cancer Surgery
Surprisingly, a high percentage of women aren't aware of the advanced products that can help restore a positive body image
ATLANTA, Oct. 16 /PRNewswire/ -- Women have more options than ever
before when facing breast
cancer. With early diagnosis, great strides have
been made in treatm...
23andMe Announces Breast Cancer Initiative
Personal Genetics Leader to Focus on Building DNA-based Community For
Women Impacted by Breast
CARLSBAD, Calif., Oct. 2 /PRNewswire/ -- 23andMe, Inc., the industry
leader in personal genetics, today announced that it is embarking on a
world-wide effort to assemble the largest cohort o...
Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
SOUTH SAN FRANCISCO, Calif., Sept. 23 /PRNewswire-FirstCall/ --
Monogram Biosciences, Inc. (Nasdaq: MGRM ) announced today that it has
initiated a study, in collaboration with the Dana-Farber Cancer Institute
(DFCI), to evaluate Monogram's HERmark(TM) Breast
Cancer Assay in
alli(TM) Partners with Breast Cancer Network of Strength(TM) to Support Women Challenged by Breast Cancer, Weight Loss or Both
Research Indicates Being Overweight Increases Risk of Breast
PARSIPPANY, N.J., Sept. 22 /PRNewswire/ -- Who knew that simply putting
on 21 - 30 pounds between your teens and your 50s could increase your risk
cancer after menopause? Now that word is getting out about the
Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
SCOTTSDALE, Ariz., Aug. 27 /PRNewswire/ -- MedPredict has published a
new report in its oncology series entitled "Thought Leader Insight &
Cancer," designed to provide critical strategic insight
for pharma and biotech companies with a stake in the market for diagnostics
Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
Monogram announces availability of HERmark and HER1 and HER3 Total Protein Assays in Collaborative Biomarker Study
SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire-FirstCall/ -- Monogram
Biosciences, Inc. (Nasdaq: MGRM ) today announced that scientific
collaborators have presente...
Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (PR) Scores
Study Published in the Journal of Clinical Oncology Proves Accurate
Measurement of ER and PR Status Using Quantitative Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)
REDWOOD CITY, Calif., June 2 /PRNewswire-FirstCall/ -- Genomic Health,
Inc. (Nasdaq: GHDX ) tod...
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
- 50% of All Evaluable Patients in Phase I Study Receiving Combination of
Bavituximab Plus Chemotherapy Achieved Objective Tumor Response or Stable Disease -
- 100% of Evaluable Patients to Date in Ongoing Phase II Breast
Cancer Study Showing Objective Tumo...